Adtran celebrates 75 years of Oscilloquartz network timing innovation
Adtran today announced that this month marks the 75th anniversary of Oscilloquartz. Founded in 1949, Oscilloquartz has evolved into a global leader in PNT network timing technology, setting numerous industry benchmarks throughout its history. The company offers precision synchronization solutions that empower customers to overcome timing challenges in sectors from telecoms to critical defense infrastructure. Over the years, Oscilloquartz has consistently led the way with groundbreaking achievements, such as introducing the industry’s first optical cesium atomic clocks with optical pumping technology, which provide unparalleled accuracy and reliability. This month also commemorates 10 years since Oscilloquartz was acquired by ADVA, now part of Adtran, helping it expand its portfolio of cost-effective timing technologies and establish the leading assured PNT platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523252321/en/
Adtran’s Oscilloquartz timing technology is playing a key role in helping organizations strengthen critical network infrastructure. (Photo: Business Wire)
“Celebrating 75 years of Oscilloquartz, alongside a decade since our integration into the Adtran family, represents a remarkable achievement. The dual anniversary highlights our enduring commitment to timing innovation and quality. Throughout these decades, we’ve navigated the evolving landscape from frequency solutions for legacy SONET/SDH to highly accurate frequency and time solutions for packet-based networks. Our dedication has enabled us to offer scalable technology that ensures robust timing, with or without satellite signals,” said Gil Biran, GM of Oscilloquartz, Adtran. “From pioneering the integration of synchronization delivery and assurance to bringing timing closer to end applications through our compact, low-power devices, including our latest family of OSAinside™ products, our portfolio has consistently addressed our customers’ key challenges. More recently, the introduction of the first commercial optical cesium atomic clocks was another major leap, significantly enhancing the precision and stability of network timing while substantially extending lifespan.”
Since its inception, Oscilloquartz has led the field in network synchronization, setting standards with the industry’s first commercial magnetic cesium atomic clock in 1966 and spearheading telecoms timing solutions in 1978. In 1982, it transformed the market by introducing the first high-performance quartz oscillators and resonators, which played a key role in developing the European Digital Cesium Standard in 1988. After its acquisition in 2014, Oscilloquartz expanded its global presence, with leading service providers adopting its products. It also provided customized solutions across metrology, finance and national defense sectors. Its leadership in cesium clock technology won support for its R&D initiatives from the European Space Agency. Continuing its legacy of innovation, Oscilloquartz recently enhanced the resiliency of GPS/GNSS systems with its Iridium®-based Satellite Time and Location (STL) technology solutions, leveraging low-Earth orbit satellite signals for more reliable, secure synchronization even in challenging environments.
“This historic anniversary is a moment to appreciate Oscilloquartz’s incredible journey, from its initial project at the astronomical observatory in Neuchâtel 70 years ago to the forefront of timing technology today,” commented Christoph Glingener, CTO of Adtran. “Over the last decade, the integration with ADVA and then Adtran has enriched Oscilloquartz’s offerings through the combined expertise of our teams. This era saw the debut of compact and cost-effective Oscilloquartz synchronization devices, delivering unmatched precision at the network edge. Its core grandmasters set new industry benchmarks with their 10GbE support and hardware timestamping. Together with Oscilloquartz’s optical atomic cesium clocks, they create a SePRTC+, guaranteeing accurate, reliable timing even during GNSS disruptions for up to 100 days. This combination of the industry’s most scalable family of grandmasters based on zero-trust architecture, coupled with optical pumping technology, sets Oscilloquartz apart today. As part of the Adtran family, Oscilloquartz will continue its legacy of excellence, keeping customers at the forefront of synchronization technology.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523252321/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
